{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:51:03Z","timestamp":1791175863875,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Diabetes Metab Disord"],"DOI":"10.1007\/s40200-026-02087-z","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:56:49Z","timestamp":1791172609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0572-780X","authenticated-orcid":false,"given":"Mohammed","family":"Al-Nusair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Eysha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanad","family":"Elchouemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam H.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2087_CR1","doi-asserted-by":"publisher","unstructured":"Palaniappan LP, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, Avery CL et al. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation [Internet]. 2026;0. Available from: https:\/\/doi.org\/10.1161\/CIR.0000000000001412","DOI":"10.1161\/CIR.0000000000001412"},{"key":"2087_CR2","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142026. Diabetes Care [Internet]. 2025;49:S183\u2013215. Available from: https:\/\/doi.org\/10.2337\/dc26-S009","DOI":"10.2337\/dc26-S009"},{"key":"2087_CR3","doi-asserted-by":"crossref","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine [Internet]. 2025;86:103363. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025002950","DOI":"10.1016\/j.eclinm.2025.103363"},{"key":"2087_CR4","doi-asserted-by":"publisher","unstructured":"Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Ann Intern Med [Internet]. 2025;178:199\u2013217. Available from: https:\/\/doi.org\/10.7326\/ANNALS-24-01590","DOI":"10.7326\/ANNALS-24-01590"},{"key":"2087_CR5","doi-asserted-by":"publisher","unstructured":"Hosseinpour A, Sood A, Kamalpour J, Zandi E, Pakmehr S, Hosseinpour H et al. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials. Clin Cardiol [Internet]. 2024;47:e24314. Available from: https:\/\/doi.org\/10.1002\/clc.24314","DOI":"10.1002\/clc.24314"},{"key":"2087_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069\u201384.","journal-title":"N Engl J Med"},{"key":"2087_CR7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390:1394\u2013407.","journal-title":"N Engl J Med"},{"key":"2087_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"2087_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26\u201336.","journal-title":"N Engl J Med"},{"key":"2087_CR10","doi-asserted-by":"publisher","unstructured":"Billings LK, Winne L, Sharma P, Gomez-Valderas E, Chivukula KK, Kwan AYM. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide. Ann Intern Med [Internet]. 2025;178:609\u201319. Available from: https:\/\/doi.org\/10.7326\/ANNALS-24-03849","DOI":"10.7326\/ANNALS-24-03849"},{"key":"2087_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184:1056\u201364.","journal-title":"JAMA Intern Med"},{"key":"2087_CR12","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393:2409\u201320.","journal-title":"N Engl J Med"},{"key":"2087_CR13","doi-asserted-by":"publisher","first-page":"e2537297","DOI":"10.1001\/jamanetworkopen.2025.37297","volume":"8","author":"CG Derington","year":"2025","unstructured":"Derington CG, Sarwal A, Wei G, Hartsell SE, Throolin M, Singh R, et al. Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes. JAMA Netw open. 2025;8:e2537297.","journal-title":"JAMA Netw open"},{"key":"2087_CR14","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1111\/dom.14497","volume":"23","author":"RE Pratley","year":"2021","unstructured":"Pratley RE, Catarig A-M, Lingvay I, Viljoen A, Paine A, Lawson J, et al. An indirect treatment comparison of the efficacy of semaglutide 1.0\u00a0mg versus dulaglutide 3.0 and 4.5\u00a0mg. Diabetes Obes Metab. 2021;23:2513\u201320.","journal-title":"Diabetes Obes Metab"},{"key":"2087_CR15","doi-asserted-by":"publisher","unstructured":"Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J et al. Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes. Sci Rep [Internet]. 2025;15:21333. Available from: https:\/\/doi.org\/10.1038\/s41598-025-06245-w","DOI":"10.1038\/s41598-025-06245-w"},{"key":"2087_CR16","doi-asserted-by":"publisher","first-page":"e70045","DOI":"10.1002\/edm2.70045","volume":"8","author":"J Wen","year":"2025","unstructured":"Wen J, Syed B, Nadora D, How-Volkman C, Bernstein E, Truong A, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol diabetes Metab. 2025;8:e70045.","journal-title":"Endocrinol diabetes Metab"},{"key":"2087_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"2087_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"2087_CR19","doi-asserted-by":"publisher","unstructured":"Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M et al. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake. Cell Metab [Internet]. 2019;30:987\u2013996.e6. Available from: https:\/\/doi.org\/10.1016\/j.cmet.2019.07.013","DOI":"10.1016\/j.cmet.2019.07.013"},{"key":"2087_CR20","doi-asserted-by":"publisher","unstructured":"Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab [Internet]. 2024;36:1534\u20131549.e7. Available from: https:\/\/doi.org\/10.1016\/j.cmet.2024.05.010","DOI":"10.1016\/j.cmet.2024.05.010"},{"key":"2087_CR21","doi-asserted-by":"publisher","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab [Internet]. 2020;31:410\u201321. Available from: https:\/\/doi.org\/10.1016\/j.tem.2020.02.006","DOI":"10.1016\/j.tem.2020.02.006"},{"key":"2087_CR22","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00125-024-06144-1","volume":"67","author":"T Karagiannis","year":"2024","unstructured":"Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67:1206\u201322.","journal-title":"Diabetologia"},{"key":"2087_CR23","doi-asserted-by":"publisher","unstructured":"Nissen SE, Wolski K, D\u2019Alessio D, Weerakkody G, Kiljanski J, Wiese RJ et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol [Internet]. 2026; Available from: https:\/\/doi.org\/10.1001\/jamacardio.2026.0767","DOI":"10.1001\/jamacardio.2026.0767"},{"key":"2087_CR24","doi-asserted-by":"publisher","unstructured":"Kr\u00fcger N, Schneeweiss S, Desai RJ, Sreedhara SK, Kehoe AR, Fuse K et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med [Internet]. 2026;32:342\u201352. Available from: https:\/\/doi.org\/10.1038\/s41591-025-04102-x","DOI":"10.1038\/s41591-025-04102-x"},{"key":"2087_CR25","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.jacadv.2025.101740","volume":"4","author":"SS Dani","year":"2025","unstructured":"Dani SS, Makwana B, Khadke S, Kumar A, Jhund P, Nasir K, et al. An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists. JACC Adv. 2025;4:101740.","journal-title":"JACC Adv"}],"container-title":["Journal of Diabetes & Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-026-02087-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40200-026-02087-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-026-02087-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:56:50Z","timestamp":1791172610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40200-026-02087-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1007\/s40200-026-02087-z","relation":{},"ISSN":["2251-6581"],"issn-type":[{"value":"2251-6581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. All data used were collected from the TriNetX platform, which contains de-identified patient data only. Thus, an institutional review board (IRB) approval and patient consent were not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosure of potential conflicts of interest: The authors did not receive support from any organization for the submitted work. The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study is exempt from informed consent. All data analyses are secondary analyses of existing data. The study does not involve intervention or interaction with human subjects. All included data are de-identified per the de-identification standard defined in Section \u00a7164.514(a) of the HIPAA Privacy Rule.","order":4,"name":"Ethics","label":"Consent to participate declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"280"}}